Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASMB NASDAQ:CPIX NASDAQ:NKTR NASDAQ:OMER On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$28.84+1.4%$24.58$7.75▼$29.40$221.63M0.662,808 shs126,183 shsCPIXCumberland Pharmaceuticals$3.46+0.4%$3.28$1.04▼$7.25$51.69M-0.41538,304 shs21,005 shsNKTRNektar Therapeutics$54.80-3.7%$43.20$6.45▼$62.95$1.04B1.18903,060 shs374,117 shsOMEROmeros$9.95-4.5%$4.37$2.95▼$13.60$686.21M2.321.58 million shs9.69 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences+0.18%+11.53%+34.21%+47.36%+53.56%CPIXCumberland Pharmaceuticals+1.78%-6.27%+1.78%-7.28%+175.20%NKTRNektar Therapeutics-0.35%+0.57%+16.06%+113.27%+193.95%OMEROmeros+154.15%+137.36%+154.77%+199.43%+153.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$28.84+1.4%$24.58$7.75▼$29.40$221.63M0.662,808 shs126,183 shsCPIXCumberland Pharmaceuticals$3.46+0.4%$3.28$1.04▼$7.25$51.69M-0.41538,304 shs21,005 shsNKTRNektar Therapeutics$54.80-3.7%$43.20$6.45▼$62.95$1.04B1.18903,060 shs374,117 shsOMEROmeros$9.95-4.5%$4.37$2.95▼$13.60$686.21M2.321.58 million shs9.69 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences+0.18%+11.53%+34.21%+47.36%+53.56%CPIXCumberland Pharmaceuticals+1.78%-6.27%+1.78%-7.28%+175.20%NKTRNektar Therapeutics-0.35%+0.57%+16.06%+113.27%+193.95%OMEROmeros+154.15%+137.36%+154.77%+199.43%+153.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASMBAssembly Biosciences 2.57Moderate Buy$41.2543.03% UpsideCPIXCumberland Pharmaceuticals 1.00SellN/AN/ANKTRNektar Therapeutics 2.63Moderate Buy$91.6767.29% UpsideOMEROmeros 2.75Moderate Buy$27.50176.35% UpsideCurrent Analyst Ratings BreakdownLatest NKTR, OMER, ASMB, and CPIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/15/2025OMEROmerosNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold10/15/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $20.0010/15/2025OMEROmerosWBB SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$45.0010/15/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.0010/14/2025ASMBAssembly BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.0010/8/2025ASMBAssembly BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CPIXCumberland PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NKTRNektar TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025OMEROmerosWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ASMBAssembly BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CPIXCumberland PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASMBAssembly Biosciences$28.52M7.76N/AN/A$5.25 per share5.49CPIXCumberland Pharmaceuticals$37.87M1.36$0.26 per share13.14$1.61 per share2.15NKTRNektar Therapeutics$98.43M10.59N/AN/A$4.94 per share11.09OMEROmerosN/AN/AN/AN/A($3.15) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASMBAssembly Biosciences-$40.18M-$5.58N/AN/AN/A-117.20%-149.01%-39.04%11/6/2025 (Estimated)CPIXCumberland Pharmaceuticals-$6.48M-$0.22N/A∞N/A-6.97%7.48%2.66%11/6/2025 (Estimated)NKTRNektar Therapeutics-$118.96M-$8.80N/AN/AN/A-163.17%-631.43%-58.21%11/6/2025 (Estimated)OMEROmeros-$156.82M-$2.11N/AN/AN/AN/AN/A-55.49%11/12/2025 (Estimated)Latest NKTR, OMER, ASMB, and CPIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025OMEROmeros-$0.58N/AN/AN/AN/AN/A11/6/2025Q3 2025ASMBAssembly Biosciences-$0.50N/AN/AN/AN/AN/A11/6/2025Q3 2025NKTRNektar Therapeutics-$2.96N/AN/AN/A$10.20 millionN/A8/14/2025Q2 2025OMEROmeros-$0.55-$0.53+$0.02-$0.43$0.31 million$28.60 million8/7/2025Q2 2025NKTRNektar Therapeutics-$3.13-$2.95+$0.18-$2.95$9.42 million$11.18 million8/6/2025Q2 2025ASMBAssembly Biosciences-$1.73-$1.33+$0.40-$1.33$5.30 million$9.63 million8/5/2025Q2 2025CPIXCumberland PharmaceuticalsN/A$0.02N/A-$0.05N/A$10.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASMBAssembly BiosciencesN/AN/AN/AN/AN/ACPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASMBAssembly BiosciencesN/A1.641.64CPIXCumberland Pharmaceuticals0.191.301.17NKTRNektar TherapeuticsN/A2.612.61OMEROmerosN/A0.810.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASMBAssembly Biosciences19.92%CPIXCumberland Pharmaceuticals15.51%NKTRNektar Therapeutics75.88%OMEROmeros48.79%Insider OwnershipCompanyInsider OwnershipASMBAssembly Biosciences5.30%CPIXCumberland Pharmaceuticals44.85%NKTRNektar Therapeutics5.25%OMEROmeros12.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASMBAssembly Biosciences1007.67 million7.27 millionOptionableCPIXCumberland Pharmaceuticals8014.96 million8.25 millionOptionableNKTRNektar Therapeutics22019.02 million18.02 millionOptionableOMEROmeros21068.06 million59.28 millionOptionableNKTR, OMER, ASMB, and CPIX HeadlinesRecent News About These CompaniesNovo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn1 hour ago | finance.yahoo.comNVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio4 hours ago | zacks.comOmeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull CaseOctober 16 at 10:11 AM | seekingalpha.comNovo Nordisk Gets New Complement System Approach to Rare Diseases With Deal for Omeros DrugOctober 16 at 10:03 AM | medcitynews.comMOmeros (OMER) Stock Rallies 149% on $2 Billion Novo Nordisk DealOctober 16 at 8:30 AM | blockonomi.comOmeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control GroupOctober 16 at 8:30 AM | businesswire.comA Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?October 16 at 4:10 AM | fool.comHims & Hers, Salesforce, Omeros, United Airlines, And Sea Ltd: Why These 5 Stocks Are On Investors' Radars TodayOctober 15 at 9:51 PM | benzinga.comOmeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug DealOctober 15 at 3:31 PM | benzinga.comNovo builds pipeline again with $2.1bn Omeros dealOctober 15 at 3:07 PM | pharmaphorum.comPNovo Nordisk Acquires Omeros’ PNH Drug in $2.1 Billion Deal: What It Means for Rare Disease TreatmentOctober 15 at 3:07 PM | sohu.comSCan OMER stock retain Novo Nordisk driven gains over the long-term?October 15 at 3:07 PM | invezz.comIOmeros rockets on news of deal with Novo NordiskOctober 15 at 3:07 PM | thepharmaletter.comTNovo wagers up to $2.1B on Omeros’ rare disease drugOctober 15 at 3:07 PM | biopharmadive.comBOmeros' (OMER) Hold Rating Reiterated at Needham & Company LLCOctober 15 at 2:12 PM | marketbeat.comOmeros (NASDAQ:OMER) Price Target Raised to $20.00 at HC WainwrightOctober 15 at 12:40 PM | marketbeat.comOmeros (NASDAQ:OMER) Earns "Strong-Buy" Rating from WBB SecuritiesOctober 15 at 12:40 PM | marketbeat.comOmeros (NASDAQ:OMER) Shares Gap Up - Here's WhyOctober 15 at 12:14 PM | marketbeat.comNovo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 BillionOctober 15 at 11:50 AM | wsj.comOmeros stock soars after $2.1 billion deal with Novo NordiskOctober 15 at 10:06 AM | za.investing.comNovo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)October 15 at 10:06 AM | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 20252 AI Stocks With Record Breaking Rallies: Can They Continue?By Dan Schmidt | September 29, 2025New Catalysts Build Positive Pressure on Intel StockBy Jeffrey Neal Johnson | September 18, 2025AST SpaceMobile's Big Win: Shares Soar on New Deal With VerizonBy Leo Miller | October 11, 2025NKTR, OMER, ASMB, and CPIX Company DescriptionsAssembly Biosciences NASDAQ:ASMB$28.84 +0.40 (+1.41%) As of 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Cumberland Pharmaceuticals NASDAQ:CPIX$3.46 +0.02 (+0.44%) As of 03:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Nektar Therapeutics NASDAQ:NKTR$54.80 -2.09 (-3.67%) As of 03:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Omeros NASDAQ:OMER$9.95 -0.47 (-4.50%) As of 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
